Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.

This study has been completed.
Sponsor:
Information provided by:
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00650832
First received: March 28, 2008
Last updated: June 2, 2011
Last verified: June 2011